Silvia Persichilli

Prof. Silvia Persichilli

orcid

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 November 2018 in Nutrients
Verified
Journal Article
Open access
PDF file
Riccardo CalvaniRiccardo Calvani
Riccardo Calvani
Anna PiccaAnna Picca
Anna Picca
Federico MariniFederico Marini
Federico Marini
Alessandra BiancolilloAlessandra Biancolillo
Alessandra Biancolillo
JGJacopo Gervasoni
Jacopo Gervasoni
Emanuele MarzettiEmanuele Marzetti
Emanuele Marzetti
Physical frailty and sarcopenia (PF&S) are hallmarks of aging that share a common pathogenic background. Perturbations in protein/amino acid metabolism may play a role in the development of PF&S. In this initial report, 68 community-dwellers aged 70 years and older, 38 with PF&S and 30 non-sarcopenic, non-frail controls (nonPF&S), were enrolled as part as the “BIOmarkers associated with Sarcopenia and Physical frailty in EldeRly pErsons” (BIOSPHERE) study. A panel of 37 serum amino acids and derivatives was assayed by UPLC-MS. Partial Least Squares–Discriminant Analysis (PLS-DA) was used to characterize the amino acid profile of PF&S. The optimal complexity of the PLS-DA model was found to be three latent variables. The proportion of correct classification was 76.6 ± 3.9% (75.1 ± 4.6% for enrollees with PF&S; 78.5 ± 6.0% for nonPF&S). Older adults with PF&S were characterized by higher levels of asparagine, aspartic acid, citrulline, ethanolamine, glutamic acid, sarcosine, and taurine. The profile of nonPF&S participants was defined by higher concentrations of α-aminobutyric acid and methionine. Distinct profiles of circulating amino acids and derivatives characterize older people with PF&S. The dissection of these patterns may provide novel insights into the role played by protein/amino acid perturbations in the disabling cascade and possible new targets for interventions.

1 June 1999 in Archives of Oral Biology
Verified
Journal Article
Closed access
BZBruno Zappacosta
Bruno Zappacosta
SPSilvia Persichilli
Silvia Persichilli
PSPasquale De Sole
Pasquale De Sole
AMAlvaro Mordente
Alvaro Mordente
BGBruno Giardina
Bruno Giardina

3 August 2021 in Cells
Verified
Journal Article
Open access
PDF file
BHBianka Hoxha
Bianka Hoxha
MHMalvina Hoxha
Malvina Hoxha
EDElisa Domi
Elisa Domi
JGJacopo Gervasoni
Jacopo Gervasoni
SPSilvia Persichilli
Silvia Persichilli
BZBruno Zappacosta
Bruno Zappacosta
Folic acid has been identified to be integral in rapid tissue growth and cell division during fetal development. Different studies indicate folic acid’s importance in improving childhood behavioral outcomes and underline its role as a modifiable risk factor for autism spectrum disorders. The aim of this systematic review is to both elucidate the potential role of folic acid in autism spectrum disorders and to investigate the mechanisms involved. Studies have pointed out a potential beneficial effect of prenatal folic acid maternal supplementation (600 µg) on the risk of autism spectrum disorder onset, but opposite results have been reported as well. Folic acid and/or folinic acid supplementation in autism spectrum disorder diagnosed children has led to improvements, both in some neurologic and behavioral symptoms and in the concentration of one-carbon metabolites. Several authors report an increased frequency of serum auto-antibodies against folate receptor alpha (FRAA) in autism spectrum disorder children. Furthermore, methylene tetrahydrofolate reductase (MTHFR) polymorphisms showed a significant influence on ASD risk. More clinical trials, with a clear study design, with larger sample sizes and longer observation periods are necessary to be carried out to better evaluate the potential protective role of folic acid in autism spectrum disorder risk.

1 February 2007 in Head & Neck
Verified
Journal Article
Closed access
PDF file
GAGiovanni Almadori
Giovanni Almadori
FBFrancesco Bussu
Francesco Bussu
JGJacopo Galli
Jacopo Galli
ALAttilio Limongelli
Attilio Limongelli
SPSilvia Persichilli
Silvia Persichilli
BGBruno Giardina
Bruno Giardina

1 January 2002 in Human & Experimental Toxicology
Verified
Journal Article
Closed access
BZB Zappacosta
B Zappacosta
SPSilvia Persichilli
Silvia Persichilli
AMAlvaro Mordente
Alvaro Mordente
AMAngelo Minucci
Angelo Minucci
DLD Lazzaro
D Lazzaro
BGB Giardina
B Giardina
Tobacco smoke is involved in the pathogenesis of several diseases regarding different body systems, mainly cardiovascular and respiratory in addition to its local toxic effect in the oral cavity. The noxious effects of smoke compounds justify the high incidence of periodontal diseases, caries, and neoplastic diseases of oral tissues in smokers. Some toxic components of tobacco smoke, unsaturated and saturated aldehydes, could interact with thiol rich compounds, leading to structural and functional modification of these molecules. Previous papers have demonstrated an in vitro significant decrease of some enzymatic activities, both in plasma and in saliva, following external addition of aldehydes or exposure to cigarette smoke (CS). Furthermore, the same studies underlined the protective effect exerted by the addition of glutathione (GSH) against the damaging role of smoke aldehydes. In this study some salivary enzymes (lactic dehydrogenase [LDH], aspartate aminotransferase [AST] and amylase), and total GSH were measured in 20 volunteers smokers, before and just after smoking a single cigarette. All enzymatic activities showed a significant inhibition following a single cigarette, probably due to the interaction between smoke aldehydes and–SH groups of the enzyme molecules. Moreover, the percentage of the enzymatic inhibition showed a negative correlation with the basal level of salivary GSH. Our results emphasize that not only one cigarette is sufficient to impair the salivary enzymatic activities but also strengthen the proposed protective role of GSH against the noxious biochemical effects of CS.